Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer
Yıl: 2015 Cilt: 25 Sayı: 1 Sayfa Aralığı: 44 - 50 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer
Öz: Akciğer kanseri, kansere bağlı ölüm nedenleri arasında erkekler ve kadınlarda ilk sırada yer almaktadır. Modern tanısal ve tedaviye yönelik gelişmelere rağmen akciğer kanseri olgularında ortalama sağ kalım %15i geçmemektedir. Bu nedenle akciğer kanserinin erken tanısı ve ayırıcı tanısında duyarlı biyobelirteçlere ihtiyaç duyulmaktadır. Bu çalışmanın amacı, akciğer kanseri hastalarında HE4 ve CYFRA 21-1 biyobelirteçlerinin tanısal etkinliğinin değerlendirilmesidir. Serum örnekleri 80 hastadan toplandı; Grup 1 akciğer kanseri tanısı alan 53 hastadan oluşmakta idi, Grup 2 ise 27 hastadan oluşan kontrol grubu idi. HE4 ve CYFRA 21-1 değerleri kemiluminesan mikropartikül immüm yöntem ile ölçüldü. HE4 için eşik değeri 70 pmol/L, CYFRA 21-1 için ise 2 ng/mL olarak belirlendi. Grup 1 için ortalama HE4 değerleri (94.79±50.56 pmol/L) Grup 2 için ölçülen değerlerden (52.00±21.06 pmol/L) istatistiksel olarak anlamlı ölçüde yüksek bulundu (p< 0.001). Grup 1 ve Grup 2 için ortalama CYFRA 21-1 değerleri sırasıyla 5.15±7.89 ng/mL ve 1.75±2.11 ng/mL olarak bulundu (p= 0.004). HE4 biyobelirtecinin duyarlılığı %73.5, CYFRA 21-1 biyobelirtecinin duyarlılığı ise %50.9 olarak saptandı. Her iki tümör biyobelirteçinin ileri evrelerde (Evre III-IV) artış oranı, erken evrelere (Evre I-II) göre anlamlı derecede yüksek bulundu (HE4 için p=0.021, CYFRA 21-1 için p= 0.003). HE4 ve CYFRA 21-1, akciğer kanseri hastalarının tanısında potansiyel biyobelirteçler olarak kullanılabilir. Özellikle HE4 yüksek duyarlılık, pozitif tahmin değeri ve tanısal etkinliği nedeni ile akciğer kanseri ayırıcı tanısında önemli biyobelirteç olmaya adaydır.
Anahtar Kelime: Konular:
Akciğer Kanseri Hastalarında HE4 ve CYFRA 21-1 in Tanısal Etkinliği
Öz: Lung cancer is the leading cause of cancer related deaths. Despite the modern diagnostic and therapeutic advances, 5-year survival rate of all cases of lung cancer does not exceed 15%. Therefore, sensitive tumor biomarkers are needed for the early detection and differential diagnosis of lung cancer. The aim of the study was to evaluate the diagnostic efficiency of HE4 (Human epididymis protein 4) and CYFRA 21-1 in patients with lung cancer. Serum samples were collected from 80 patients; Group 1 consisted of 53 patients with lung cancer and Group 2 consisted of 27 patients as control. HE4 and CYFRA 21.1 levels were measured by chemiluminescent microparticle immunoassay (CMIA). The cut-off limits for HE4 was 70 pmol/L and 2 ng/mL for CYFRA 21-1. Serum mean HE4 levels in Group 1 (94.79±50.56 pmol/L) were significantly higher than that of Group 2 (52.00±21.06 pmol/L), (p< 0.001). CYFRA 21-1 levels in Group 1 and Group 2 were 5.15±7.89 ng/mL and 1.75±2.11 ng/mL, respectively (p= 0.004). The sensitivity rates were 73.5% for HE4 and 50.9% for CYFRA 21-1. Both tumor markers were clearly related to stage with significantly higher ratio of increase in advanced stages (III-IV) than in early stages (I-II), (p= 0.021 for HE4, p=0.003 for CYFRA 21-1). HE4 and CYFRA 21.1 might be used as potential diagnostic markers for lung cancer patients. Especially HE4 may be candidate as a leading-marker for the discrimination of lung cancer because of its high sensitivity, positive predictive value and diagnostic accuracy.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Boring CC, Squires TS, Tong T. Cancer Statistics. CA Cancer J Clin 42: 19-38,1992.
- Muley T, Fetz TH, Dienemann H, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60: 408-415, 2008.
- Dikmen E, Kara M, Dikmen G, et al. Detection of telomerase activity in bronchial lavage as an adjunct to cytological diagnosis in lung cancer. Eur J Cardiothorac Surg. 23: 194-199, 2003.
- Herthlein L, Stieber P, Kirschenhofer A, et al. Human Epididymis protein 4(HE4) in benign and malignant diseases. Clin Chem Lab Med 50: 2181-2188, 2012.
- Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res 5: 20, 2012.
- Moore RG, Miller MC, Eklund EE, et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206: 349.e1-7, 2012.
- Moore RG, Miller MC, Steinhoff MM, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 206: 351. e1-8, 2012.
- Bolstad N, Øijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 33: 141-148, 2012.
- Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40-46, 2009.
- Li J, Dowdy S, Tipton T, Podratz K, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9: 555-566, 2009.
- Van den Heuvel MM, Korse CM, Bonfrei JMG, Baas P. Noninvasive diagnosis of pleural malignancies: The role of tumor markers. Lung Cancer 59: 350-354, 2008.
- Muley T, Fetz TH, Dienemann H, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60: 408-415, 2008.
- Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in Advanced Stage Non-Small Cell Lung Cancer. Clin Cancer Res 9: 1728-1733, 2003.
- Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 108: 163- 169, 1995.
- Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154: 725-733, 1996.
- Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2: 402-407, 2007.
- Pfannschmidt J, Muley T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 55: 371-377, 2007.
- Koike T, Tsuchiya R, Goya T, et al. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol 2: 408-413, 2007.
- Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 33: 1141-1149, 2012.
- Liu W, Yang J, Chi PD, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis 17: 1346-1353, 2013.
- Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 32: 265-271, 2011.
- Yamashita S, Tokuishi K, Moroga T, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 33: 2365-2370, 2012.
- Higgins KA, Chino JP, Ready N, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol 7: 1141-1147, 2012.
| APA | DİKMEN E, GÜNGÖR A, DİKMEN Z, Akbıyık F (2015). Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. , 44 - 50. |
| Chicago | DİKMEN Erkan,GÜNGÖR Adem,DİKMEN Z. Günnur,Akbıyık Filiz Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. (2015): 44 - 50. |
| MLA | DİKMEN Erkan,GÜNGÖR Adem,DİKMEN Z. Günnur,Akbıyık Filiz Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. , 2015, ss.44 - 50. |
| AMA | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. . 2015; 44 - 50. |
| Vancouver | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. . 2015; 44 - 50. |
| IEEE | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F "Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer." , ss.44 - 50, 2015. |
| ISNAD | DİKMEN, Erkan vd. "Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer". (2015), 44-50. |
| APA | DİKMEN E, GÜNGÖR A, DİKMEN Z, Akbıyık F (2015). Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. Uluslararası Hematoloji-Onkoloji Dergisi, 25(1), 44 - 50. |
| Chicago | DİKMEN Erkan,GÜNGÖR Adem,DİKMEN Z. Günnur,Akbıyık Filiz Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. Uluslararası Hematoloji-Onkoloji Dergisi 25, no.1 (2015): 44 - 50. |
| MLA | DİKMEN Erkan,GÜNGÖR Adem,DİKMEN Z. Günnur,Akbıyık Filiz Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. Uluslararası Hematoloji-Onkoloji Dergisi, vol.25, no.1, 2015, ss.44 - 50. |
| AMA | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. Uluslararası Hematoloji-Onkoloji Dergisi. 2015; 25(1): 44 - 50. |
| Vancouver | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer. Uluslararası Hematoloji-Onkoloji Dergisi. 2015; 25(1): 44 - 50. |
| IEEE | DİKMEN E,GÜNGÖR A,DİKMEN Z,Akbıyık F "Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer." Uluslararası Hematoloji-Onkoloji Dergisi, 25, ss.44 - 50, 2015. |
| ISNAD | DİKMEN, Erkan vd. "Diagnostic Efficiency of HE4 and CYFRA 21-1 in Patients with Lung Cancer". Uluslararası Hematoloji-Onkoloji Dergisi 25/1 (2015), 44-50. |
